Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Sunday, Wall Street Zen reports.
COLL has been the subject of a number of other reports. Leerink Partners initiated coverage on Collegium Pharmaceutical in a report on Wednesday, September 9th. They issued an "outperform" rating and a $45.00 price target for the company. Barclays reduced their price objective on Collegium Pharmaceutical from $56.00 to $48.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 19th. Truist Financial assumed coverage on shares of Collegium Pharmaceutical in a research note on Wednesday, September 9th. They set a "buy" rating and a $49.00 target price for the company. Oppenheimer initiated coverage on shares of Collegium Pharmaceutical in a report on Wednesday, September 23rd. They set an "outperform" rating and a $50.00 target price on the stock. Finally, Piper Sandler decreased their price target on shares of Collegium Pharmaceutical from $43.00 to $28.00 and set a "neutral" rating for the company in a report on Friday, November 6th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $44.88.
View Our Latest Analysis on Collegium Pharmaceutical
Collegium Pharmaceutical Stock Up 1.5%
COLL stock traded up $0.37 during mid-day trading on Friday, hitting $25.32. 394,691 shares of the company were exchanged, compared to its average volume of 644,982. The company has a current ratio of 1.01, a quick ratio of 0.87 and a debt-to-equity ratio of 3.44. The company has a market capitalization of $786.95 million, a PE ratio of 25.32, a price-to-earnings-growth ratio of 0.78 and a beta of 0.75. Collegium Pharmaceutical has a twelve month low of $21.43 and a twelve month high of $50.79. The firm has a fifty day simple moving average of $23.04 and a 200 day simple moving average of $32.26.
Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported $1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.10. Collegium Pharmaceutical had a return on equity of 85.14% and a net margin of 4.68%. The firm had revenue of $216.34 million for the quarter, compared to analysts' expectations of $216.03 million. During the same quarter in the prior year, the firm posted $2.25 earnings per share. Collegium Pharmaceutical's revenue for the quarter was up 67.4% compared to the same quarter last year. On average, research analysts forecast that Collegium Pharmaceutical will post 6.42 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Collegium Pharmaceutical
Several hedge funds and other institutional investors have recently modified their holdings of COLL. BlackRock Inc. acquired a new position in Collegium Pharmaceutical during the 2nd quarter valued at about $196,972,000. Jupiter Topco LLC acquired a new position in shares of Collegium Pharmaceutical during the second quarter worth approximately $77,743,000. Janus Henderson Group PLC boosted its position in shares of Collegium Pharmaceutical by 26.0% during the first quarter. Janus Henderson Group PLC now owns 1,825,651 shares of the specialty pharmaceutical company's stock worth $60,358,000 after buying an additional 377,073 shares during the period. Dimensional Fund Advisors LP grew its holdings in Collegium Pharmaceutical by 0.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 833,192 shares of the specialty pharmaceutical company's stock worth $27,551,000 after buying an additional 2,712 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in Collegium Pharmaceutical by 29.4% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 703,528 shares of the specialty pharmaceutical company's stock worth $23,266,000 after buying an additional 159,755 shares in the last quarter.
About Collegium Pharmaceutical
(
Get Free Report)
Collegium Pharmaceutical is a U.S.-based specialty pharmaceutical company focused on developing and commercializing medicines for pain management. Its portfolio includes Xtampza ER, an extended-release oxycodone product; Belbuca, a buprenorphine buccal film for chronic pain; and Nucynta, tapentadol tablets available in immediate- and extended-release formulations. The company also markets Symproic, a treatment for opioid-induced constipation. Collegium's products include extended-release and opioid medicines, and the company emphasizes responsible use and risk-mitigation measures in its commercial activities.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Collegium Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Collegium Pharmaceutical wasn't on the list.
While Collegium Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.